Trial Profile
Human Metabolism of Ornithine Phenylacetate: A Study in Healthy Volunteers
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ornithine phenylacetate (Primary)
- Indications Hepatic encephalopathy; Liver cirrhosis; Liver failure; Non-alcoholic fatty liver disease
- Focus Pharmacokinetics
- Acronyms OCERA OP
- 10 Apr 2019 Planned End Date changed from 1 Apr 2018 to 1 Apr 2021.
- 24 May 2017 New trial record